| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/27/2005 | US20050020869 Methods of enhancing radiation effects with metal nanoparticles |
| 01/27/2005 | US20050020665 For example, N-hydroxy-N-(1-benzo[b]thien-2-ylethyl) acetamide,1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxy urea,N-hydroxy-N-(1-benzo[b]thien-2-ylethyl)-N'-methyl urea |
| 01/27/2005 | US20050020502 Sincalide formulations |
| 01/27/2005 | US20050019763 Isolated polypeptide of given sequence; expression vectors, host cells, antibodies, agonists, and antagonists; use in diagnosing, treating, or preventing various disorders |
| 01/27/2005 | US20050019410 dissolving particles in solvents and then precipitation by mixing the solutions with nonsolvents and spray drying to form microstructure particles; imaging contrast enhancing agents used for medical diagnosis |
| 01/27/2005 | US20050019338 Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
| 01/27/2005 | US20050019267 Macromolecular imaging agents for liver imaging |
| 01/27/2005 | US20050019266 Therapeutic ultrasond; imaging vascular plaque; administering contrast agent in aqueous carrier; scanning |
| 01/27/2005 | US20050019265 Polymersomes incorporating highly emissive probes |
| 01/27/2005 | US20050019264 Imaging tissue with contrast agent such as Rose Bengal; medical diagnosis |
| 01/27/2005 | US20050019263 Conjugate for differentiating between healthy and unhealthy tissue |
| 01/27/2005 | US20050019262 Post-biopsy cavity treatment implants and methods |
| 01/27/2005 | US20050019260 Animal model for allergy |
| 01/27/2005 | US20050019258 Therapy for incontinence; insertion of cooling fluid into bladder of guinea pig in prevence of test drug; measuring reduction of transition point of bladder contraction ; drug screening |
| 01/27/2005 | US20050019255 Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| 01/27/2005 | US20050019253 Using concentration of pancreatic exocrine enzymes visualized by 13C-labeled oligosaccharide or polysaccharide to detect pancreatitis and/or pancreatic cancer |
| 01/27/2005 | US20050019252 Diagnostic agents for pancreatic exocrine function |
| 01/27/2005 | DE202004014789U1 Stent for implantation into or onto a hollow organ comprises a cutout serving as receptacle for a conical marker element which is X-ray opaque and is oriented radially relative to the stent axis |
| 01/26/2005 | EP1499617A1 Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
| 01/26/2005 | EP1499614A1 Adenosine a3 receptor modulators |
| 01/26/2005 | EP1499362A1 Fusions of cytokines and tumor targeting proteins |
| 01/26/2005 | EP1499318A2 Peptide deformylase activated prodrugs |
| 01/26/2005 | EP1499292A1 In vivo imaging of apoptosis |
| 01/26/2005 | EP1265942B1 Use of poly(diallylamine) polymers |
| 01/26/2005 | EP0948361B1 Magnetic resonance blood pool agents |
| 01/26/2005 | EP0831909B1 Use of a protoporphyrin ix precursor in the treatment of dermatophytoses and malaria after photoactivation of said protoporphyrin |
| 01/26/2005 | CN1571680A PACAP compositions and methods for tumor imaging and therapy |
| 01/25/2005 | US6846915 Gadolinium (III) complexes as magnetic resonance imaging contrast enhancers |
| 01/25/2005 | CA2443927C Method for viewing tumor tissue located within a body cavity |
| 01/25/2005 | CA2123224C Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of t-lymphocytes |
| 01/20/2005 | WO2005006356A1 Magnetic nanoparticles having improved magnetic properties |
| 01/20/2005 | WO2005005626A1 Yellow fever mosquito deoxyribonucleoside kinases and its use |
| 01/20/2005 | WO2005005479A1 Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor |
| 01/20/2005 | WO2005004992A2 Magnetic resonance contrast-enhancing agents and method for detecting and imaging artherosclerotic plaque |
| 01/20/2005 | WO2005004883A2 Compound testing method |
| 01/20/2005 | WO2005004800A2 Trypanosome derived apoptotic factors (taf) |
| 01/20/2005 | WO2005004781A1 Non-invasive intravascular thrombolyisis using modified ultrasound techniques |
| 01/20/2005 | WO2005004592A2 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications |
| 01/20/2005 | WO2004083944A3 Polarized light devices and methods |
| 01/20/2005 | WO2004064742A9 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms |
| 01/20/2005 | WO2004050698A3 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy |
| 01/20/2005 | WO2004033488B1 Peptide mediated synthesis of metallic and magnetic materials |
| 01/20/2005 | WO2003057155A3 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 01/20/2005 | US20050014828 Compositions containing prodrugs of florfenicol and methods of use |
| 01/20/2005 | US20050014821 Compounds and methods for treating neurodegenerative disorders |
| 01/20/2005 | US20050014693 Transmission and, or amplification of signals; oral or enteric administering, dissolving, absorption of peptide yy; obesity therapy |
| 01/20/2005 | US20050014686 Somatostatin analogues |
| 01/20/2005 | US20050014207 Monoclonal antibody hPAM4 |
| 01/20/2005 | US20050013780 Hollow microspheres with controlled fragility for medical use |
| 01/20/2005 | US20050013779 Direct in vivo analysis; injecting fluorescence indicator, irradiating and reflecting excitation light to external detector; simplified alignment |
| 01/20/2005 | US20050013778 Detecting localization of labeled annexin or fragment |
| 01/20/2005 | US20050013777 Method for detecting at least one substance in a metabolic process of a living being and device for carrying out the method |
| 01/20/2005 | US20050013776 Obtaining control data from long term study; subjecting sample groups to same diet program for varied time periods; comparing results to control |
| 01/20/2005 | CA2536354A1 Atopic dermatitis inducer |
| 01/20/2005 | CA2534090A1 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications |
| 01/20/2005 | CA2529304A1 Non-invasive intravascular thrombolysis using modified ultrasound techniques |
| 01/20/2005 | CA2528669A1 Compositions and methods for treating and diagnosing cancer |
| 01/20/2005 | CA2524771A1 Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor |
| 01/19/2005 | EP1498146A2 In vivo assay and molecular markers for testing the phenotypic stability. |
| 01/19/2005 | EP1497647A1 Test for measurement of therapeutic drug levels |
| 01/19/2005 | EP1497454A2 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| 01/19/2005 | EP1497304A2 Dual-labeled nucleotides |
| 01/19/2005 | EP1496942A1 Microparticles comprising carbohydrate beads covalently linked with allergen |
| 01/19/2005 | EP1496863A2 Preparation and use of a stable formulation of allosteric effector compounds |
| 01/19/2005 | EP1496802A2 Process for identifying and treating specified cell types |
| 01/19/2005 | EP1423019A4 Process for preparing concentrate thickener compositions |
| 01/19/2005 | CN1568187A 2H-2, 3-dinitrogen phenodiazine-1-ketone and using method thereof |
| 01/19/2005 | CN1566947A Primate animal model for SARS related coronary virus, its construction method and use thereof |
| 01/19/2005 | CN1185210C Use of naphthalene-carboxylic acid for preparing a medicament used for treating diseases characterized by amyloid aggregation sedimentation |
| 01/18/2005 | US6844166 Using fluorescence resonance energy transfer to evaluate ability of carbohydrates to displace bound glycoconjugates |
| 01/18/2005 | US6844165 For diagnosis, drug discovery; both parallel and muliplex analyte processing capabilities; retentate chromatography is a combinatorial method to provide high information resolution of analytes in complex mixtures |
| 01/18/2005 | US6843980 Methods for using annexin for detecting cell death in vivo and treating associated conditions |
| 01/18/2005 | US6843979 Radiolabeled compounds useful as imaging agents for visualizing the location and density of serotonin transporter by tomography imaging; as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction |
| 01/13/2005 | WO2005002557A1 Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| 01/13/2005 | WO2004098649A3 Apparatus and method for examining an object by means of elastically scattered x-ray radiation and contrast agent |
| 01/13/2005 | US20050010126 Assessment of concentration of inhalational compounds in the brain |
| 01/13/2005 | US20050009802 Tertiary amino-substituted, e.g, 1(4),8(11),15(18),22(25)-tetrakis[(3-(dimethylamino)phenoxy)phthalocyaninato] zinc; and their use as photodynamic therapeutic and photodiagnostic agents. |
| 01/13/2005 | US20050009127 Using glucagon like peptide binding activity as diagnostic tool in detecting modulator of impaired glucose tolerance |
| 01/13/2005 | US20050009117 Using phycoerythrine as stain to detect and classify tumor cells; tissue targeted therapy; antitumor agents |
| 01/13/2005 | US20050009074 Implantable monitor of vulnerable plaque and other disease states |
| 01/13/2005 | US20050008646 Screening fir cytotoxic end points; cancerous disease modifying antibodies |
| 01/13/2005 | US20050008574 Use of intravenous contrast media for projection mammography |
| 01/13/2005 | US20050008573 Diagnosis of tumors; in vivo imaging |
| 01/13/2005 | US20050008572 Biocompatibility; sustained release |
| 01/13/2005 | US20050008570 Gadolinum complex for magnetic resonance imaging contrast agent |
| 01/13/2005 | US20050008569 Contract agent for imaging; ultrasonic , magnetic resonance imaging, computer temography; gadolinum, or compound thereof, encapsulated in shell; cancer therapy |
| 01/12/2005 | EP1495130A1 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 01/12/2005 | EP1495031A1 Labeled oxazinocarbazoles as diagnostic agents |
| 01/12/2005 | EP1494721A2 Cavity filling biopsy site marker |
| 01/12/2005 | EP1494699A2 Methods for inhibiting vascular hyperpermeability |
| 01/12/2005 | EP1494694A2 Photo-active backbone cyclized somatostatin analogs for photodynamic therapy and imaging |
| 01/12/2005 | EP1494584A1 Endohedral metallofullerene contrast agents |
| 01/12/2005 | CN1564944A Phenotypic effects of ubiquinone deficiencies and methods of screening thereof |
| 01/12/2005 | CN1564829A Antibodies to insulin-like growth factor I receptor |
| 01/12/2005 | CN1562376A Method for preparing magnetic resonance contrast medium in microminiature and superparamagnetism |
| 01/11/2005 | CA2020489C Carboxamide non-ionic contrast media |
| 01/06/2005 | WO2005002293A2 Cox-2-targeted imaging agents |
| 01/06/2005 | WO2005001906A2 Materials and methods for near-infrared and infrared lymph node mapping |
| 01/06/2005 | WO2005001415A2 Optically pure and enriched isomers of chelating ligands and contrast agents |
| 01/06/2005 | WO2005000361A1 Menthol-containing preparation |